Lucy H.Y. Young, M.D., Ph.D.
Associate Professor of Ophthalmology


Massachusetts Eye & Ear Infirmary
Howe Laboratory
243 Charles Street
Boston, MA 02114
Tel.: (617) 573-3710

 

 

Ocular melanoma is the most common intraocular malignancy in adults and is associated with a high incidence of metastases. Life expectancy of patients with metastatic disease is generally less than one year.

The long-term objective of our research is to establish photodynamic therapy as a safe and effective regimen in the treatment of ocular melanoma. We believe ocular melanoma is an ideal candidate for photodynamic therapy as it is easily visualized through dilated pupils and is accessible to direct illumination.

In our laboratory, we have developed an animal model of pigmented choroidal melanoma and with this model, we have shown effective photodestruction of tumors using various photosensitizer agents. We have developed a photosensitizer angiographic method to evaluate the biodistribution of photosensitizer agents through the eye in order to determine the ideal treatment time for each new photosensitizer dye. In addition, we are currently trying to determine whether dynamic MRI can be applied to evaluate treatment response. Lastly, we are also using a novel, two-photon excitation technique in our photodynamic therapy work. This new activation system uses longer wavelength light which penetrates tissue more deeply and should therefore be more effective for the treatment of thicker tumors.

The development of an effective photodynamic therapy that eradicates melanoma cells more selectively could enhance survival and provide better visual outcome for patients afflicted with ocular melanoma.

Research          Publications       Lab Members        Links

Howe Home Page